<DOC>
	<DOCNO>NCT01759485</DOCNO>
	<brief_summary>Background : Despite improvement medication , treatment delivery rehabilitation , schizophrenia outcome remain suboptimal . There proportion 30-40 % treatment-resistant schizophrenia patient . Multiple line evidence suggest vitamin D neuro-active steroid act brain development , lead alteration brain neurochemistry adult brain function . Early deficiency link neuropsychiatric disorder , schizophrenia , adult deficiency associate adverse brain outcome , include Parkinson 's disease , Alzheimer 's disease , depression cognitive decline . Ecological study support potential role vitamin D schizophrenia . These data include study explore association schizophrenia winter/spring birth also apparent increase incidence prevalence schizophrenia high latitude . Objective : To evaluate effect vitamin-D supplementation mental state clozapine-treated chronic schizophrenia patient , relation disease severity serum vitamin D level . Methods : investigator use prospective , interventional , longitudinal , double blind , placebo-controlled , randomized design . The investigator recruit 50 clozapine-treated chronic schizophrenia patient , low level serum vitamin-D , randomly assign ( 1:1 ratio ) receive either weekly oral drop vitamin D ( Cholecalciferol ) oral drop placebo 8 week follow-up . Repeated assessment include : clinical severity scale ( PANSS , CGI ) , side effect ( SAS , BARS , clozapine side effect ) , cognitive ( MoCA ) , metabolic parameter laboratory data . Patients assign placebo supplement vitamin D 8 week period , assess protocol vitamin D treat patient . All participant assess 24 week vitamin D initiation . Analysis : investigator use on-way ANOVA repeat measure comparison vitamin D control group . The investigator apply intention treat LOCF .</brief_summary>
	<brief_title>Vitamin D Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>1 . Males females 2 . Age 1865 year 3 . Diagnosis schizophrenia accord DSMIVTR criterion , confirm two senior psychiatrist 4 . Total PANSS score &gt; 70 5 . CGIS &gt; 3 6 . Clozapine treatment least 18 week 7 . Vitamin D deficiency : plasma 25OHVitamin D &lt; 75 nmol/L ( 2030 ng/mL ) 8 . Able consume oral drop vitaminD 9 . Able sign inform consent 1 . Mental retardation 2 . Organic brain disease 3 . Known parathyroid disorder 4 . Inborn/acquired vitamin D metabolism disorder 5 . Patients already treat vitamin D supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Clozapine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Vitamin-D</keyword>
	<keyword>Treatment-resistant</keyword>
</DOC>